Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $121.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/11/15 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (AKBLF) Snapshot

Open
$121.00
Previous Close
$121.00
Day High
$121.00
Day Low
$121.00
52 Week High
07/28/14 - $144.75
52 Week Low
12/11/14 - $113.00
Market Cap
1.2B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
9.2M
EX-Date
03/13/15
P/E TM
--
Dividend
$4.77
Dividend Yield
0.58%
Current Stock Chart for ALK-ABELLO A/S (AKBLF)

Related News

No related news articles were found.

alk-abello a/s (AKBLF) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s (AKBLF) Details

ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies worldwide. The company offers allergy immunotherapy products as injections, sublingual drops, and sublingual tablets for various allergies, including grass, ragweed, house dust mite, tree, cat, bee, and wasp. It also offers adrenaline auto-injectors for the treatment of severe allergic reactions. In addition, the company’s development programs include GRAZAX for grass allergic (ARC) and asthma prevention; GRASTEK for grass ARC; RAGWITEK for ragweed ARC; house dust mite (HDM) sublingual tablet-based allergy immunotherapy (SLIT)-tablets for HDM asthma and rhinitis; tree SLIT-tablet for tree ARC; and Japanese cedar SLIT-tablet for cedar tree ARC. It has strategic partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize SLIT-tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

1,829 Employees
Last Reported Date: 05/5/15
Founded in 1923

alk-abello a/s (AKBLF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

alk-abello a/s (AKBLF) Key Developments

ALK-Abelló A/S Reports Unaudited Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for 2015

ALK-Abello A/S reported unaudited earnings results for the first quarter of 2015. For the first quarter, the company reported revenue of DKK 650 million against DKK 684 million a year ago. Operating profit before depreciation and amortisation (EBITDA) was DKK 128 million against DKK 206 million a year ago. Operating profit (EBIT) was DKK 91 million against DKK 174 million a year ago. Profit before tax (EBT) was DKK 159 million against DKK 183 million a year ago. Net profit was DKK 89 million against DKK 108 million a year ago. Cash flow from operating activities was DKK 31 million against DKK 93 million a year ago. Earnings per share (DEPS), diluted was DKK 9 against DKK 11 a year ago. Cash flow per share (CFPS) was DKK 3 against DKK 10 a year ago. Exchange rate developments impacted revenue growth positively by approximately 4% points. Cash flow decrease was primarily caused by lower milestone payments. Additions, intangible assets were DKK 9 million against DKK 18 million a year ago. Additions, tangible assets were DKK 25 million against DKK 18 million a year ago. For 2015, ALK still expects to grow revenue in the base business by 0-5% in local currencies based on low, single-digit growth in Europe and high single-digit growth in non-European markets. Growth initiatives are expected to outweigh the impact of European austerity measures. To reflect current exchange rates, reported revenue in the base business is now expected at DKK 2.25-2.35 billion (previously DKK 2.2-2.3 billion). Operating profit (EBITDA before special items), excluding sales royalties and milestone payments from partnerships, is expected in the range of DKK 225 - DKK 300 million. Exchange rates are not expected to materially affect EBITDA. CAPEX is projected at approximately DKK 200 million, while free cash flow is expected to be negative in the range of DKK 100 - DKK 200 million.

ALK-Abelló Seeks Acquisitions

ALK-Abelló A/S (CPSE:ALK B) is looking for acquisition opportunities. Flemming Pedersen, Chief Financial Officer and Executive Vice President of ALK-Abelló said, "We continue to assess our options in other markets. We are working on initiatives in Asia and South America where we will either setup our own companies, look to acquire local companies or possibly enter partnerships."

ALK-Abelló A/S, Q1 2015 Earnings Call, May 05, 2015

ALK-Abelló A/S, Q1 2015 Earnings Call, May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBLF:US $121.00 USD 0.00

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 21.38 GBp 0.00
DBV Technologies SA €43.03 EUR -0.59
Merck & Co Inc $59.64 USD -0.065
Sanofi €89.74 EUR -2.53
Stallergenes SA €56.69 EUR +0.69
View Industry Companies
 

Industry Analysis

AKBLF

Industry Average

Valuation AKBLF Industry Range
Price/Earnings 50.5x
Price/Sales 3.3x
Price/Book 3.3x
Price/Cash Flow 47.2x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.